RxDoctor Payments Data

Julius Tabe, MD

Family Medicine · Holliston, MANPI 1801093356

Payments from drug & device makers

$808in general payments, 2019–2025

Across 11 payments — averaging $73.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$622
  • Neurocrine Biosciences, Inc.$135
  • Pfizer$30
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$22

What the payments were for

  • Food & beverage$808100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$808 in reported general payments places this provider in the 80th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$570,632
Medicare patients
741
Services billed
5,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,931$404,410
NuplazidPimavanserin Tartrate53$133,342
XareltoRivaroxaban221$52,663
ProcritEpoetin Alfa21$47,562
JardianceEmpagliflozin134$34,257
Risperdal ConstaRisperidone Microspheres23$30,235
XifaxanRifaximin20$26,534
FarxigaDapagliflozin Propanediol87$22,564
TrulicityDulaglutide33$21,929
JanuviaSitagliptin Phosphate107$21,855
MyrbetriqMirabegron79$18,962
Atorvastatin Calcium2,089$18,855
LantusInsulin Glargine,hum.Rec.Anlog217$18,009
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$17,763
Mirtazapine1,048$16,530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$404,4101,931 claims
Acadia Pharmaceuticals IncNuplazid$622$133,34253 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$22$26,53420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Holliston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →